Scale-Up Of An ELEVECTA Transient rAAV Production Process In The Xcellerex X-Platform Single-Use Bioreactor

By Kelly Cybulski, Malin Kruukka, Johanna Viiliäinen, Ben Hudjetz, Michael Mühle, Anne MacIntyre, and Timothy Erlandson, Cytiva

Recombinant adeno-associated virus (rAAV) therapies continue to gain traction as viable treatments for a range of diseases, but scalable, high-yield manufacturing remains a key hurdle. Recent advancements demonstrate that the ELEVECTA transient cell line, when paired with the next-generation Xcellerex X-platform single-use bioreactor and GMP-grade HyClone prime expression medium, offers a robust solution. This integrated approach supports high-density cell growth and consistent, high-titer rAAV production across multiple serotypes, with reduced levels of encapsidated host cell DNA. Importantly, the process has been successfully scaled to 200 L, maintaining performance and yield, which positions it as a strong candidate for commercial-scale manufacturing.

For teams navigating the complexities of rAAV production, learn more about a compelling model for achieving both quality and scalability.